1. 103PAfatinib is active in osteosarcoma in vitro models. (5th March 2018) Authors: Cruz Ramos, M; Zamudio-Cuevas, Y; Martínez-Flores, K; Medina-Luna, D; Martínez-Nava, G; Fernández-Torres, J; López Reyes, A; Solca, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 63ONRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib. (24th November 2019) Authors: Goto, Y; Cadranel, J; Weinberg, B A; Duruisseaux, M; Liu, S V; Tolba, K; Branden, E; Doebele, R C; Heining, C; Schlenk, R F; Laskin, J J; Cheema, P K; Jones, M R; Trombetta, D; Muscarella, L A; Cseh, A; Solca, F; Renouf, D J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-291NRG1-fusion positive gastrointestinal tumours: afatinib as a novel potential treatment option. (2nd July 2019) Authors: Weinberg, B; Renouf, D; Lim, H; Heining, C; Schlenk, R; Jones, M; Liu, S; Cseh, A; Solca, F; Laskin, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗